Reata gets another shot in Friedreich’s ataxia

With Reata Pharmaceuticals’ investors focused on the group’s upcoming pivotal readout with bardoxolone, its second most advanced project, omaveloxolone, has understandably received relatively little attention.

There is another good reason for this: the chances of the asset getting a positive result in a mid-stage trial in Friedreich’s ataxia look slim after a previous flop in this rare neurological disease.